-
Mercado PD-1 inhibitor approved by the US FDA for the treatment of cervical cancer patients
On January 14th, Merck announced on January 12th local time that the US Food and Drug Administration (FDA) has approved Merck's PD-1 inhibitor Keytruda in combination with radiotherapy and chemothera ... -
Pfizer ADC drug TIVDAK has been fully approved by the US FDA for the treatment of recurrent or metastatic cervical cancer
Pfizer ADC drug TIVDAK has been fully approved by the US FDA for the treatment of recurrent or metastatic cervical cancer. On May 6th, Zaiding Pharmaceuticals announced on its official WeChat account ... -
Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
Merck announced that its PD-1 inhibitor pembrolizumab (trade name: pembrolizumab) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of locally advanc ... -
Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
On December 10th, Merck announced that its PD-1 inhibitor pembrolizumab (trade name: CRDA®) Approved by the National Medical Products Administration (NMPA) of China, the combination of radiothera ... -
Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
According to AI News, on December 10th, Merck announced that its PD-1 inhibitor pembrolizumab (trade name: CRDA& reg;) Approved by the National Medical Products Administration (NMPA) of China, the co ...